Filing summary
Entity and period: The supplied filing is IsoRay, Inc.’s Form 10-Q for the quarter and six months ended December 31, 2017, filed February 9, 2018. This does not match the request metadata naming Perspective Therapeutics, Inc.; verify the issuer before relying on this summary. Amounts below are in U.S. dollars, generally in thousands unless stated otherwise.
Financial performance
| Metric | Three months ended Dec. 31, 2017 | Six months ended Dec. 31, 2017 |
|---|---|---|
| Net product sales | $1,536; up 49% year over year | $2,747; up 30% |
| Gross profit and margin | $531; 35% (prior year: $(1)) | $796; 29% (prior year: $47; 2%) |
| Operating expenses | $1,999 | $3,816 |
| Operating loss | $(1,468) | $(3,020) |
| Net loss applicable to common shareholders | $(1,466) | $(3,015) |
| Loss per share | $(0.03) | $(0.05) |
Prostate brachytherapy generated 86% of quarterly and 87% of six-month sales. Sales growth was attributed to a full sales team, renewed sales and marketing efforts, and new and reactivated accounts. Gross margin improvement reflected procurement savings, lower staffing costs, and cost allocation changes, partly offset by higher isotope supply costs.
Cash, liquidity, and capital
- At December 31, cash and cash equivalents were $2.951 million, certificates of deposit were $2.725 million, and restricted cash was $181,000. Cash plus certificates of deposit totaled $5.676 million.
- Six-month operating cash use was $3.184 million, compared with $3.014 million a year earlier. Cash declined $2.981 million from June 30 to $2.951 million.
- Working capital was $6.486 million (June 30: $9.185 million); the current ratio was 7.96 (prior fiscal year-end: 9.30). Total liabilities were $1.507 million, including a $576,000 asset retirement obligation. No borrowings or debt balance are disclosed in the supplied filing text.
- Investing cash flow was positive $164,000, largely reflecting certificates of deposit maturities and purchases; financing cash flow was positive $39,000, including option exercise proceeds and preferred dividends paid.
Outlook, risks, and notable items
- Management expected cash and certificates of deposit to cover projected operating needs through the remainder of fiscal 2018 and into the first half of fiscal 2019. Separately, it said the company would need to raise capital within three to six months to maintain its NYSE American listing, assuming budgeted expenses and projected revenues.
- Management projected at least 20% fiscal 2018 revenue growth over fiscal 2017; the target was missed in the first quarter but exceeded in the second. Cash-flow break-even was projected in three to five years only if growth targets and strategy are achieved; management gave no assurance.
- The company planned approximately $400,000 of additional investment in production automation over 18 months. It had invested approximately $412,000 cumulatively in automation through December 31, 2017. A new production and administration facility was designed, but construction depended on financing.
- Customer concentration is material: five customers represented approximately 46% of six-month revenue, with one customer at approximately 24%. The filing warns that losing a major customer could materially harm revenue.
- IsoRay reported a GammaTile collaboration and a January 3, 2018 manufacturing and supply agreement. Supply of the product depends on FDA 510(k) clearance; the agreement provides for a 10-year term and initial seed pricing of $130–$150 depending on order quantity.
- A media advertising agreement was terminated in December 2017. The company had paid $60,000 and issued 250,000 immediately vested warrants at $0.54 per share; the warrants generated approximately $72,000 of share-based compensation expense.
- A shareholder derivative lawsuit was dismissed on October 19, 2017, and the matter was resolved. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Key facts for investors to verify
- Confirm the issuer: the filing is for IsoRay, Inc., not Perspective Therapeutics, Inc.
- Reconcile the apparent tension between management’s projected cash runway into fiscal 2019 and its stated need to raise capital within three to six months to preserve the exchange listing.
- Track actual revenue growth, gross margins, cash burn, and progress toward the conditional break-even outlook.
- Assess dependence on a small number of customers and exposure to competition in prostate cancer treatment.
- Verify FDA clearance timing, commercial terms, and execution of the GammaTile supply arrangement, as well as the financing and cost assumptions for the planned facility and automation spending.